These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 37982768)

  • 21. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
    Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
    Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current Clinical Applications of In Vivo Gene Therapy with AAVs.
    Mendell JR; Al-Zaidy SA; Rodino-Klapac LR; Goodspeed K; Gray SJ; Kay CN; Boye SL; Boye SE; George LA; Salabarria S; Corti M; Byrne BJ; Tremblay JP
    Mol Ther; 2021 Feb; 29(2):464-488. PubMed ID: 33309881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials.
    Zhao X; Meng L; Chen Y
    BMJ Open; 2021 Feb; 11(2):e040906. PubMed ID: 33550238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Open-Label Phase II Study Assessing the Safety of Bilateral, Sequential Administration of Retinal Gene Therapy in Participants with Choroideremia: The GEMINI Study.
    MacLaren RE; Audo I; Fischer MD; Huckfeldt RM; Lam BL; Pennesi ME; Sisk R; Gow JA; Li J; Zhu K; Tsang SF
    Hum Gene Ther; 2024 Aug; 35(15-16):564-575. PubMed ID: 38970425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration.
    Fuller-Carter PI; Basiri H; Harvey AR; Carvalho LS
    BioDrugs; 2020 Dec; 34(6):763-781. PubMed ID: 33136237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.
    Maguire AM; High KA; Auricchio A; Wright JF; Pierce EA; Testa F; Mingozzi F; Bennicelli JL; Ying GS; Rossi S; Fulton A; Marshall KA; Banfi S; Chung DC; Morgan JI; Hauck B; Zelenaia O; Zhu X; Raffini L; Coppieters F; De Baere E; Shindler KS; Volpe NJ; Surace EM; Acerra C; Lyubarsky A; Redmond TM; Stone E; Sun J; McDonnell JW; Leroy BP; Simonelli F; Bennett J
    Lancet; 2009 Nov; 374(9701):1597-605. PubMed ID: 19854499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Photobiomodulation for non-exudative age-related macular degeneration.
    Henein C; Steel DH
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013029. PubMed ID: 34097768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hereditary Retinal Dystrophy.
    Hohman TC
    Handb Exp Pharmacol; 2017; 242():337-367. PubMed ID: 28035529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational Engineering and Preclinical Evaluation of Neddylation and SUMOylation Site Modified Adeno-Associated Virus Vectors in Murine Models of Hemophilia B and Leber Congenital Amaurosis.
    Maurya S; Mary B; Jayandharan GR
    Hum Gene Ther; 2019 Dec; 30(12):1461-1476. PubMed ID: 31642343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Road towards Gene Therapy for X-Linked Juvenile Retinoschisis: A Systematic Review of Preclinical Gene Therapy in Cell-Based and Rodent Models of XLRS.
    van der Veen I; Heredero Berzal A; Koster C; Ten Asbroek ALMA; Bergen AA; Boon CJF
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of gene transfer for Leber's congenital amaurosis.
    Maguire AM; Simonelli F; Pierce EA; Pugh EN; Mingozzi F; Bennicelli J; Banfi S; Marshall KA; Testa F; Surace EM; Rossi S; Lyubarsky A; Arruda VR; Konkle B; Stone E; Sun J; Jacobs J; Dell'Osso L; Hertle R; Ma JX; Redmond TM; Zhu X; Hauck B; Zelenaia O; Shindler KS; Maguire MG; Wright JF; Volpe NJ; McDonnell JW; Auricchio A; High KA; Bennett J
    N Engl J Med; 2008 May; 358(21):2240-8. PubMed ID: 18441370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety and efficacy of gene therapy treatment for monogenic retinal and optic nerve diseases: A systematic review.
    Britten-Jones AC; Jin R; Gocuk SA; Cichello E; O'Hare F; Hickey DG; Edwards TL; Ayton LN
    Genet Med; 2022 Mar; 24(3):521-534. PubMed ID: 34906485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset.
    Newman NJ; Yu-Wai-Man P; Carelli V; Moster ML; Biousse V; Vignal-Clermont C; Sergott RC; Klopstock T; Sadun AA; Barboni P; DeBusk AA; Girmens JF; Rudolph G; Karanjia R; Taiel M; Blouin L; Smits G; Katz B; Sahel JA;
    Ophthalmology; 2021 May; 128(5):649-660. PubMed ID: 33451738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results.
    Feuer WJ; Schiffman JC; Davis JL; Porciatti V; Gonzalez P; Koilkonda RD; Yuan H; Lalwani A; Lam BL; Guy J
    Ophthalmology; 2016 Mar; 123(3):558-70. PubMed ID: 26606867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiotherapy for neovascular age-related macular degeneration.
    Evans JR; Igwe C; Jackson TL; Chong V
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD004004. PubMed ID: 32844399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial.
    Koilkonda RD; Yu H; Chou TH; Feuer WJ; Ruggeri M; Porciatti V; Tse D; Hauswirth WW; Chiodo V; Boye SL; Lewin AS; Neuringer M; Renner L; Guy J
    JAMA Ophthalmol; 2014 Apr; 132(4):409-20. PubMed ID: 24457989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy : preparation for gene therapy clinical trial.
    Lam BL; Feuer WJ; Schiffman JC; Porciatti V; Vandenbroucke R; Rosa PR; Gregori G; Guy J
    JAMA Ophthalmol; 2014 Apr; 132(4):428-36. PubMed ID: 24525545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. scAAVengr, a transcriptome-based pipeline for quantitative ranking of engineered AAVs with single-cell resolution.
    Öztürk BE; Johnson ME; Kleyman M; Turunç S; He J; Jabalameli S; Xi Z; Visel M; Dufour VL; Iwabe S; Pompeo Marinho LFL; Aguirre GD; Sahel JA; Schaffer DV; Pfenning AR; Flannery JG; Beltran WA; Stauffer WR; Byrne LC
    Elife; 2021 Oct; 10():. PubMed ID: 34664552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AAV Gene Augmentation Therapy for CRB1-Associated Retinitis Pigmentosa.
    Alves CH; Wijnholds J
    Methods Mol Biol; 2018; 1715():135-151. PubMed ID: 29188511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.
    Bennett J; Wellman J; Marshall KA; McCague S; Ashtari M; DiStefano-Pappas J; Elci OU; Chung DC; Sun J; Wright JF; Cross DR; Aravand P; Cyckowski LL; Bennicelli JL; Mingozzi F; Auricchio A; Pierce EA; Ruggiero J; Leroy BP; Simonelli F; High KA; Maguire AM
    Lancet; 2016 Aug; 388(10045):661-72. PubMed ID: 27375040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.